Interventional Software for Multi-immunotherapy of Solid Tumors

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Lung Cancer · Liver Cancer · Solid Tumor, Adult

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Contact: Study coordinator (Zhang Zhenfeng, MD, PhD) · zhangzhf@gzhmu.edu.cn · +862039195966

Study leads

Zhenfeng Zhang, MD, PhD
Principal Investigator
Second Affiliated Hospital of Guangzhou Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · La Jolla, United States

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Birmingham, United States · Anchorage, United States

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Lund, Sweden

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Small-cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Shanghai, China